{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T14:46:48Z","timestamp":1790261208131,"version":"4.1.0"},"reference-count":36,"publisher":"American Society for Microbiology","issue":"8","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2016,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>\n                    Increasing resistance in Gram-negative bacilli, including\n                    <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Klebsiella<\/jats:named-content>\n                    spp., has reduced the utility of broad-spectrum cephalosporins. Avibactam, a novel non-\u03b2-lactam \u03b2-lactamase inhibitor, protects \u03b2-lactams from hydrolysis by Gram-negative bacteria that produce extended-spectrum \u03b2-lactamases (ESBLs) and serine carbapenemases, including Ambler class A and\/or class C and some class D enzymes. In this analysis, we report the\n                    <jats:italic>in vitro<\/jats:italic>\n                    activity of ceftazidime-avibactam and comparators against multidrug-resistant (MDR)\n                    <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Klebsiella<\/jats:named-content>\n                    spp. from the 2012-2014 INFORM surveillance study. Isolates collected from 176 sites were sent to a central laboratory for confirmatory identification and tested for susceptibility to ceftazidime-avibactam and comparator agents, including ceftazidime alone. A total of 2,821 of 10,998 (25.7%)\n                    <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Klebsiella<\/jats:named-content>\n                    species isolates were classified as MDR, based on resistance to three or more classes of antimicrobials. Among the MDR isolates, 99.4% had an ESBL screen-positive phenotype, and 27.4% were not susceptible to meropenem as an example of a carbapenem. Ceftazidime-avibactam was highly active against MDR isolates, including ESBL-positive and serine carbapenemase-producing isolates, with MIC\n                    <jats:sub>50\/90<\/jats:sub>\n                    values of 0.5\/2 \u03bcg\/ml and 96.6% of all MDR isolates and ESBL-positive MDR isolates inhibited at the FDA breakpoint (MIC value of \u22648 \u03bcg\/ml). Ceftazidime-avibactam did not inhibit isolates producing class B enzymes (metallo-\u03b2-lactamases) either alone or in combination with other enzymes. These\n                    <jats:italic>in vitro<\/jats:italic>\n                    results support the continued investigation of ceftazidime-avibactam for the treatment of MDR\n                    <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Klebsiella<\/jats:named-content>\n                    species infections.\n                  <\/jats:p>","DOI":"10.1128\/aac.02841-15","type":"journal-article","created":{"date-parts":[[2016,5,24]],"date-time":"2016-05-24T12:26:28Z","timestamp":1464092788000},"page":"4677-4683","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":37,"title":["Assessment of the\n                    <i>In Vitro<\/i>\n                    Activity of Ceftazidime-Avibactam against Multidrug-Resistant Klebsiella spp. Collected in the INFORM Global Surveillance Study, 2012 to 2014"],"prefix":"10.1128","volume":"60","author":[{"given":"Meredith","family":"Hackel","sequence":"first","affiliation":[{"name":"International Health Management Associates, Schaumburg, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krystyna M.","family":"Kazmierczak","sequence":"additional","affiliation":[{"name":"International Health Management Associates, Schaumburg, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daryl J.","family":"Hoban","sequence":"additional","affiliation":[{"name":"International Health Management Associates, Schaumburg, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas J.","family":"Biedenbach","sequence":"additional","affiliation":[{"name":"International Health Management Associates, Schaumburg, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel K.","family":"Bouchillon","sequence":"additional","affiliation":[{"name":"International Health Management Associates, Schaumburg, Illinois, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boudewijn L. M.","family":"de Jonge","sequence":"additional","affiliation":[{"name":"AstraZeneca Pharmaceuticals, Waltham, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory G.","family":"Stone","sequence":"additional","affiliation":[{"name":"AstraZeneca Pharmaceuticals, Waltham, Massachusetts, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dks460"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.12023"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2014.03.026"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(08)70041-0"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.49.7.3018-3020.2005"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.00036-08"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2008.896"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1111\/nyas.12010"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0013-7"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00641-09"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00756-10"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.11.4.589"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.48.8.3203-3206.2004"},{"key":"e_1_3_2_15_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01019-15"},{"key":"e_1_3_2_16_2","article-title":"A global assessment of the in vitro activity of ceftazidime-avibactam against multi-drug-resistant Klebsiella spp.\u2014INFORM Surveillance Program, poster E-1685","author":"Hackel M","year":"2013","unstructured":"Hackel M, Hoban D, Biedenbach D, Badal R, Morrissey I, Bouchillon S, Stone G. 2013. A global assessment of the in vitro activity of ceftazidime-avibactam against multi-drug-resistant Klebsiella spp.\u2014INFORM Surveillance Program, poster E-1685. Abstr 53rd Intersci Conf Antimicrob Agents Chemother.","journal-title":"Abstr 53rd Intersci Conf Antimicrob Agents Chemother"},{"key":"e_1_3_2_17_2","volume-title":"CLSI document M07-A9","author":"Clinical and Laboratory Standards Institute","year":"2012","unstructured":"Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standards, 9th ed. CLSI document M07-A9. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"9"},{"key":"e_1_3_2_18_2","volume-title":"CLSI document M100-S25","author":"Clinical and Laboratory Standards Institute","year":"2015","unstructured":"Clinical and Laboratory Standards Institute. 2015. Performance standards for antimicrobial susceptibility testing; twenty-fourth informational supplement. CLSI document M100-S25. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_2_19_2","volume-title":"Tygacil: tigecycline FDA prescribing information","author":"Pfizer, Inc","year":"2010","unstructured":"Pfizer, Inc. 2010. Tygacil: tigecycline FDA prescribing information. Pfizer, Inc., Collegeville, PA."},{"key":"e_1_3_2_20_2","volume-title":"Avycaz: ceftazidime-avibactam prescribing information","author":"Forest Pharmaceuticals Inc","year":"2014","unstructured":"Forest Pharmaceuticals Inc. 2014. Avycaz: ceftazidime-avibactam prescribing information. Forest Pharmaceuticals Inc., Cincinnati, OH."},{"key":"e_1_3_2_21_2","unstructured":"European Committee on Antimicrobial Susceptibility Testing. 2015. Breakpoint tables for interpretation of MICs and zone diameters version 5.0 valid from 2015-01-01. http:\/\/www.eucast.org\/clinical_breakpoints\/."},{"key":"e_1_3_2_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2012.08.025"},{"key":"e_1_3_2_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05186-14"},{"key":"e_1_3_2_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkn353"},{"key":"e_1_3_2_25_2","doi-asserted-by":"publisher","DOI":"10.4065\/mcp.2010.0674"},{"key":"e_1_3_2_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.05035-11"},{"key":"e_1_3_2_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1574-6976.2011.00268.x"},{"key":"e_1_3_2_28_2","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/249856"},{"key":"e_1_3_2_29_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku237"},{"key":"e_1_3_2_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03057-14"},{"key":"e_1_3_2_31_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dku568"},{"key":"e_1_3_2_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.04238-14"},{"key":"e_1_3_2_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01165-15"},{"key":"e_1_3_2_34_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2011.09.012"},{"key":"e_1_3_2_35_2","first-page":"8","article-title":"The growing resistance of Klebsiella pneumoniae; the need to expand our antibiogram: case report and review of the literature","volume":"7","author":"Garbati MA","year":"2013","unstructured":"Garbati MA, Godhair AI. 2013. The growing resistance of Klebsiella pneumoniae; the need to expand our antibiogram: case report and review of the literature. Afr J Infect Dis 7:8\u201310.","journal-title":"Afr J Infect Dis"},{"key":"e_1_3_2_36_2","doi-asserted-by":"publisher","DOI":"10.1159\/000320943"},{"key":"e_1_3_2_37_2","doi-asserted-by":"publisher","DOI":"10.1098\/rstb.1980.0049"}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02841-15","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.02841-15","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T15:52:04Z","timestamp":1645458724000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.02841-15"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":36,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["10.1128\/AAC.02841-15"],"URL":"https:\/\/doi.org\/10.1128\/aac.02841-15","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.726377282.793536918","asserted-by":"object"}]},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"2015-11-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-05-12","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-07-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}